Payment overview · 2025
General Payments
$822.14
33 reported records · 13 companies
Healthcare provider profile · identity verified
Faina Kogan, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · BROOKLYN, NY · NPI 1144374380
Verified facts
What the public records show
CMS Open Payments records show Faina Kogan, MD received $822.14 in general payments during 2025 across 33 reported records.
ABBVIE INC. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Prolia, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $188.97 | 23.0% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $159.61 | 19.4% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.52 | 10.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.02 | 9.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.72 | 7.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $54.83 | 6.7% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $50.16 | 6.1% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $38.63 | 4.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.77 | 3.3% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $26.42 | 3.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.14 | 2.3% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.28 | 2.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.07 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $822.14 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $162.65 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $159.61 | 8 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $159.61 | 8 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $64.72 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $56.94 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $56.94 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $56.94 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $55.52 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $54.83 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $50.16 | 2 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $38.63 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $26.77 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $26.42 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $26.32 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.32 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 42 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 162 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 38 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
42 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
162 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
123 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
38 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 568 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 499 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 449 | 114 |
| Losartan Potassium | Losartan Potassium | 383 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 378 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 350 | 89 |
| Metformin Hcl | Metformin Hcl | 276 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 170 | 38 |
| Linzess | Linaclotide | 162 | 24 |
| Gabapentin | Gabapentin | 161 | 47 |
| Allopurinol | Allopurinol | 155 | 30 |
| Simvastatin | Simvastatin | 144 | 35 |
| Furosemide | Furosemide | 131 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 30 |
| Omeprazole | Omeprazole | 127 | 39 |
| Vascepa | Icosapent Ethyl | 126 | 31 |
| Irbesartan | Irbesartan | 125 | 27 |
| Carvedilol | Carvedilol | 124 | 32 |
| Synthroid | Levothyroxine Sodium | 123 | 28 |
| Famotidine | Famotidine | 122 | 28 |
| Sertraline Hcl | Sertraline Hcl | 122 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 28 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 114 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 40 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 111 | 15 |
| Atenolol | Atenolol | 108 | 24 |
| Januvia | Sitagliptin Phosphate | 102 | 12 |
| Lisinopril | Lisinopril | 101 | 28 |
| Glipizide Er | Glipizide | 97 | 19 |
| Montelukast Sodium | Montelukast Sodium | 97 | 21 |
| Finasteride | Finasteride | 95 | 21 |
| Tradjenta | Linagliptin | 93 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 25 |
| Enalapril Maleate | Enalapril Maleate | 84 | 17 |
| Zenpep | Lipase/Protease/Amylase | 83 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 22 |
| Jardiance | Empagliflozin | 82 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 17 |
| Eliquis | Apixaban | 79 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 78 | 21 |
| Farxiga | Dapagliflozin Propanediol | 75 | 13 |
| Memantine Hcl | Memantine Hcl | 70 | 13 |
| Metformin Hcl Er | Metformin Hcl | 68 | 18 |
| Ozempic | Semaglutide | 66 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 23 |
| Dexlansoprazole Dr | Dexlansoprazole | 65 | suppressed |
| Glimepiride | Glimepiride | 64 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 17 |
| Ezetimibe | Ezetimibe | 56 | 13 |
| Donepezil Hcl | Donepezil Hcl | 52 | 16 |
| Mounjaro | Tirzepatide | 52 | 11 |
| Ammonium Lactate | Ammonium Lactate | 49 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 40 |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 43 | suppressed |
| Creon | Lipase/Protease/Amylase | 42 | 18 |
| Lidocaine | Lidocaine | 42 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 41 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 41 | 11 |
| Azelastine Hcl | Azelastine Hcl | 39 | 11 |
| Baclofen | Baclofen | 39 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 39 | suppressed |
| Mesalamine | Mesalamine | 38 | suppressed |
| Prolia | Denosumab | 38 | 25 |
| Trazodone Hcl | Trazodone Hcl | 38 | suppressed |
| Dutasteride | Dutasteride | 37 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 36 | 12 |
| Meloxicam | Meloxicam | 36 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 12 |
| Celecoxib | Celecoxib | 33 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 31 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | 12 |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 29 | suppressed |
| Cyclosporine | Cyclosporine | 28 | suppressed |
| Nateglinide | Nateglinide | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Estradiol | Estradiol | 27 | 16 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | 11 |
| Cilostazol | Cilostazol | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Prednisone | Prednisone | 23 | 18 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Dexilant | Dexlansoprazole | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Unithroid | Levothyroxine Sodium | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Crestor | Rosuvastatin Calcium | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Motegrity | Prucalopride Succinate | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Jublia | Efinaconazole | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Rapaflo | Silodosin | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Plavix | Clopidogrel Bisulfate | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Uloric | Febuxostat | 12 | suppressed |
| Uroxatral | Alfuzosin Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Restasis Multidose | Cyclosporine | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $822.14 · 33 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Arikayce, BREZTRI, Brinsupri, COMIRNATY, CONTRAVE, CREON, ECC Solutions, EVENITY, GEMTESA, IBSRELA, INSPIRE, LINZESS, PREVNAR 20, PROLIA, QULIPTA, SHINGRIX, Symbravo, TRINTELLIX, UBRELVY, VYNDAQEL | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error